126 related articles for article (PubMed ID: 11069489)
1. Melanoma erysipeloides: successful treatment by chemoimmunotherapy.
Hillen U; Willers C; Goos M
Br J Dermatol; 2000 Oct; 143(4):904-6. PubMed ID: 11069489
[No Abstract] [Full Text] [Related]
2. What's new in the treatment of melanoma?
Dummer R; Burg G
J Eur Acad Dermatol Venereol; 2000 Sep; 14(5):337-9. PubMed ID: 11305369
[No Abstract] [Full Text] [Related]
3. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
4. [Linear porokeratosis].
Darrigade AS; Conte H; Ip Kan Fong H; Taïeb A; Jouary T
Ann Dermatol Venereol; 2011 Nov; 138(11):800-2. PubMed ID: 22078049
[No Abstract] [Full Text] [Related]
5. [Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Conill C; Puig S; Toscas I; Castel T
Med Clin (Barc); 2002 Nov; 119(19):758-9. PubMed ID: 12487980
[No Abstract] [Full Text] [Related]
6. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
7. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
9. Management of malignant melanoma: best practices.
Smylie M; Claveau J; Alanen K; Taillefer R; George R; Wong R; Mason WP;
J Cutan Med Surg; 2009; 13(2):55-73. PubMed ID: 19459245
[TBL] [Abstract][Full Text] [Related]
10. [Use of local magnitothermia in the treatment of patients with primary-confined skin melanoma].
Korovin SI; Tolstopiatov BA; Medinets IuR; Protsenko VV; Dedkov AG; Palivets AIu; Smakova MS
Lik Sprava; 2002; (1):129-33. PubMed ID: 11944360
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of melanoma].
Dréno B; Wallon-Dumont G
Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
[TBL] [Abstract][Full Text] [Related]
14. [Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate].
Strannegärd O; Thorén FB; Lundgren E
Lakartidningen; 2008 Feb 6-12; 105(6):358-61. PubMed ID: 18380352
[No Abstract] [Full Text] [Related]
15. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model.
Wack C; Becker JC; Bröcker EB; Lutz WK; Fischer WH
Melanoma Res; 2001 Jun; 11(3):247-53. PubMed ID: 11468513
[TBL] [Abstract][Full Text] [Related]
16. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
17. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
18. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.
Groenewegen G; de Gast GC
Eur J Cancer; 1999 Aug; 35 Suppl 3():S23-4. PubMed ID: 10645217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
